Novo Nordisk A/S (NVO)
122.86
+0.11
(+0.09%)
USD |
NYSE |
Apr 19, 12:37
Novo Nordisk Cash from Operations (TTM): 15.81B for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 15.81B |
September 30, 2023 | 15.97B |
June 30, 2023 | 12.91B |
March 31, 2023 | 11.92B |
December 31, 2022 | 11.18B |
September 30, 2022 | 9.272B |
June 30, 2022 | 9.642B |
March 31, 2022 | 10.49B |
December 31, 2021 | 8.752B |
September 30, 2021 | 9.024B |
June 30, 2021 | 8.815B |
March 31, 2021 | 8.306B |
December 31, 2020 | 7.960B |
September 30, 2020 | 8.949B |
June 30, 2020 | 8.326B |
March 31, 2020 | 6.988B |
December 31, 2019 | 7.015B |
September 30, 2019 | 7.465B |
June 30, 2019 | 6.718B |
March 31, 2019 | 6.953B |
December 31, 2018 | 7.067B |
September 30, 2018 | 6.515B |
June 30, 2018 | 7.081B |
March 31, 2018 | 6.152B |
December 31, 2017 | 6.266B |
Date | Value |
---|---|
September 30, 2017 | 7.162B |
June 30, 2017 | 7.130B |
March 31, 2017 | 7.809B |
December 31, 2016 | 7.181B |
September 30, 2016 | 7.073B |
June 30, 2016 | 6.651B |
March 31, 2016 | 6.179B |
December 31, 2015 | 5.696B |
September 30, 2015 | 5.510B |
June 30, 2015 | 5.793B |
March 31, 2015 | 5.528B |
December 31, 2014 | 5.653B |
September 30, 2014 | 5.301B |
June 30, 2014 | 4.346B |
March 31, 2014 | 4.115B |
December 31, 2013 | 4.619B |
September 30, 2013 | 4.017B |
June 30, 2013 | 4.151B |
March 31, 2013 | 4.102B |
December 31, 2012 | 3.836B |
September 30, 2012 | 4.169B |
June 30, 2012 | 4.332B |
March 31, 2012 | 4.041B |
December 31, 2011 | 3.993B |
September 30, 2011 | 4.241B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
6.718B
Minimum
Jun 2019
15.97B
Maximum
Sep 2023
9.764B
Average
8.949B
Median
Sep 2020
Cash from Operations (TTM) Benchmarks
Amgen Inc | 8.471B |
AstraZeneca PLC | 10.34B |
Sanofi SA | -- |
Viking Therapeutics Inc | -73.38M |
Evaxion Biotech AS | -- |